Melatonin (2) – Slenyto®
Sleep disorders in neurogenetic diseases; ≥ 2 to ≤ 18 years of age
Characteristics
| Start date | 01.10.2024 |
|---|---|
| Resolution | 17.10.2024 |
| INN | Melatonin |
| Brand name | Slenyto® |
| Pharm. company | InfectoPharm Arzneimittel und Consilium GmbH |
| G-BA Procedure ID | D-1117 |
| Therapeutic area | Nervous system diseases Sleep disorders / Insomnia / Excessive daytime sleepiness (EDS) |
| Reason for procedure | not completed: discontinued |
Associated procedures
| Melatonin (2) | Slenyto® | InfectoPharm Arzneimittel und Consilium GmbH | Sleep disorders in neurogenetic diseases; ≥ 2 to ≤ 18 years of age | n.d. | discontinued | |
| Melatonin (1) | Slenyto® | InfectoPharm Arzneimittel und Consilium GmbH | Sleep disorders |
0
8,000–86,000 |
100% Hint for minor additional benefit repealed |
<< List of all resolutions